Rani Therapeutics Holdings, Inc. SEC Filings

Rani Therapeutics (RANI) filed its Q3 2025 10‑Q, reporting lower operating expenses and a narrower quarterly loss. Q3 operating expenses were $7.3 million versus $11.8 million a year ago, driving a net loss of $7.9 million compared to $12.7 million in Q3 2024. Year to date, the company recorded contract revenue of $172,000 and a net loss of $31.9 million.

Liquidity remained tight at quarter‑end with cash, cash equivalents and restricted cash of $4.6 million, total assets of $10.1 million, and current debt of $13.5 million. Stockholders’ equity stood at a deficit of $12.0 million. Management notes that October 2025 financing events, a Chugai license and collaboration upfront, Series D warrant exercises, and a lender debt conversion alleviated substantial doubt about going concern for the next 12 months.

During 2025, Rani raised funds via a July securities purchase agreement ($3.0 million gross) and $3.9 million in cash from warrant exercises tied to a May letter agreement, issuing 13,160,172 Series D warrants at a $0.65 exercise price. As of October 31, 2025, Rani had 97,541,221 Class A shares and 23,970,359 Class B shares outstanding.

Rani Therapeutics Holdings, Inc. furnished an 8‑K announcing a corporate update and financial results for the three and nine months ended September 30, 2025. The company issued a press release on November 6, 2025, which is included as Exhibit 99.1 and incorporated by reference.

The information provided under Item 2.02, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act, and will only be incorporated into other filings if specifically referenced.

Rani Therapeutics (RANI): Director equity grant reported. A director was granted a stock option covering 100,000 shares of Class A common stock on 10/23/2025 at an exercise price of $2.09 per share. The option expires on 10/22/2035.

The award vests over three years: one-third on October 23, 2026, then one‑thirty‑sixth monthly thereafter, subject to continuous service. Following the grant, 100,000 derivative securities were beneficially owned, held directly.

Rani Therapeutics Holdings, Inc. reported a Form 3 insider filing. The filing shows a director reported no securities beneficially owned as of 10/23/2025. The document indicates it was filed by one reporting person.

Rani Therapeutics Holdings, Inc. (RANI) reported a Form 4 showing a director received a stock option grant for 100,000 shares of Class A common stock at an exercise price of $2.09 per share on October 23, 2025.

The option expires on October 22, 2035 and vests over three years: one-third on October 23, 2026, then 1/36 monthly thereafter, subject to continuous service. Following the grant, 100,000 derivative securities were beneficially owned directly.

Rani Therapeutics Holdings, Inc. (RANI) reported an initial beneficial ownership filing (Form 3) for director Abraham Bassan. The filing states that no securities are beneficially owned as of the event date 10/23/2025. The form was filed by one reporting person and reflects the individual’s status as a director, with no non-derivative or derivative holdings listed.

Rani Therapeutics (RANI) reported insider activity: Director and 10% owner Mir A. Imran purchased 2,083,334 shares of Class A common stock at $0.605 on 10/23/2025 in a PIPE offering. He also acquired warrants to purchase 2,083,334 Class A shares with a $0.48 exercise price, which are exercisable upon stockholder approval and carry a five-year term from the date of such approval.

Following the transactions, he beneficially owns 2,083,334 Class A shares directly. Indirect holdings are reported as 74,139 Class A shares and 22,660,053 Class B shares through affiliated entities, subject to stated pecuniary interest disclaimers.

Rani Therapeutics Holdings, Inc. closed a private placement of 42,633,337 shares of Class A common stock, together with warrants to purchase up to 125,000,004 shares and pre-funded warrants to purchase up to 82,366,667 shares. Following the closing, shares outstanding were 97,541,221.

In connection with the financing, Andrew Farquharson and Maulik Nanavaty resigned from the board effective upon closing. The company appointed Abraham Bassan and Vasudev Bailey, Ph.D. to the board, naming Mr. Bassan chair of Nominating and Corporate Governance and Dr. Bailey chair of Compensation. For so long as Samsara BioCapital and Anomaly Ventures each beneficially own at least 25% of the securities issued to it at closing (including upon exercise of the warrants), each has the right to designate one board member, subject to Nasdaq rules.

Rani Therapeutics (RANI) reported insider share sales on a Form 4. The reporting person executed open‑market sales of Class A common stock on two dates. On 10/20/2025, they sold 1,923,000 shares at a weighted average price of $2.4115. On 10/21/2025, they sold 4,000,000 shares at a weighted average price of $2.7685.

Following these transactions, the reporting person beneficially owned 2,379,194 shares, held indirectly through South Lake One LLC. The filing notes that the weighted average prices reflect multiple trades within ranges of $2.25–$2.61 and $2.50–$3.09, and detailed trade breakdowns are available upon request. The ownership is reported as indirect, and the form was filed by one reporting person.